CancerDrs

Colorectal Cancer clinical trials in Texas

116 actively recruiting colorectal cancer trials at 41 sites across Texas.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 3 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 2, Phase 3 Recruiting Academic/Other

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.

Sponsor: NRG Oncology
NCT ID: NCT05174169
Sites in Texas:
  • The Don and Sybil Harrington Cancer Center — Amarillo, Texas
  • Dell Seton Medical Center at The University of Texas — Austin, Texas
  • University of Texas at Austin — Austin, Texas
  • Saint Joseph Regional Cancer Center — Bryan, Texas
  • UT MD Anderson - The Woodlands — Conroe, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

The purpose of this study is to learn more about a new medicine called PF-08634404, and how well it works in people with cancer of the colon or rectum (CRC)). The goal is to understand if the new study medicine, combined with chemotherapy …

Sponsor: Pfizer
NCT ID: NCT07222800
Sites in Texas:
  • Texas Oncology - West Texas — Abilene, Texas
  • Texas Oncology - West Texas — Amarillo, Texas
  • Texas Oncology - Gulf Coast — Beaumont, Texas
  • Texas Oncology - Northeast Texas — Denison, Texas
  • Texas Oncology - Northeast Texas — Denton, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer

This study is being done to answer the following questions: Is the chance of rectal cancer responding the same if chemotherapy alone is given before limited surgery compared to chemotherapy and radiation therapy given together before limit…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06205485
Sites in Texas:
  • UT MD Anderson Cancer Center — Houston, Texas
  • Scott and White Memorial Hospital — Temple, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) versus Bevacizumab in Combination with FOLFOX for the First-line Tr…

Sponsor: Summit Therapeutics
NCT ID: NCT07228832
Sites in Texas:
  • Clinical Study Site — Dallas, Texas
  • Clinical Study Site — Dallas, Texas
  • Clinical Study Site — Fort Worth, Texas
  • Clinical Study Site — Tyler, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

The purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, oxalipl…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06662786
Sites in Texas:
  • Texas Oncology West Texas — Abilene, Texas
  • Texas Oncology DFW — Dallas, Texas
  • UT Southwestern — Dallas, Texas
  • MD Anderson Cancer Center — Houston, Texas
  • Baylor Scott and White Health 1 — Round Rock, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

The purpose of this study is to evaluate the efficacy and safety of standard-of-care chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite stable colorectal cancer.

Sponsor: Incyte Corporation
NCT ID: NCT07284849
Sites in Texas:
  • Ascension Seton Spclty Care Ctr — Austin, Texas
  • Texas Oncology — Austin, Texas
  • University of Texas Southwestern Medical Center — Dallas, Texas
  • Md Anderson Cancer Center — Houston, Texas
  • Baylor Scott & White Health — Temple, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

This phase III trial compares hepatic arterial infusion (HAI) (pump chemotherapy) in addition to standard of care chemotherapy versus standard of care chemotherapy alone in treating patients with colorectal cancer that has spread to the li…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT05863195
Sites in Texas:
  • Parkland Memorial Hospital — Dallas, Texas
  • UT Southwestern Simmons Cancer Center - RedBird — Dallas, Texas
  • UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
  • UT Southwestern/Simmons Cancer Center-Fort Worth — Fort Worth, Texas
  • UT Southwestern Clinical Center at Richardson/Plano — Richardson, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

The primary purpose of this study is to evaluate the efficacy of perioperative dostarlimab compared with standard of care (SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instab…

Sponsor: GlaxoSmithKline
NCT ID: NCT05855200
Sites in Texas:
  • GSK Investigational Site — Dallas, Texas
  • GSK Investigational Site — Dallas, Texas
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

The purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untreated, unresectable, or metastatic color…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT07221357
Sites in Texas:
  • Texas Oncology Dallas Fort Worth West (DFWW) - Arlington Cancer Center North — Arlington, Texas
  • Texas Oncology, PA — Austin, Texas
  • Baylor College of Medicine Medical Center — Houston, Texas
  • Texas Oncology - San Antonio — San Antonio, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

Researchers are looking for other ways to treat locally advanced or metastatic colorectal cancer (mCRC) that is unresectable and has a gene mutation called KRAS G12C. Standard (or usual) treatments for this type of colorectal cancer may in…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06997497
Sites in Texas:
  • Texas Oncology - DFW ( Site 8002) — Dallas, Texas
  • UT Southwestern Medical Center ( Site 0059) — Dallas, Texas
  • Texas Oncology - Northeast Texas ( Site 8001) — Denison, Texas
  • Texas Oncology - San Antonio ( Site 8004) — San Antonio, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis

The main goal of this clinical trial is to learn if the drug eRapa works to slow down the progression of disease in patients diagnosed with Familial Adenomatous Polyposis (FAP). Researchers will compare eRapa to Placebo. The questions to b…

Sponsor: Rapamycin Holdings Inc.
NCT ID: NCT06950385
Sites in Texas:
  • The University of Texas MD Anderson Cancer Center — Houston, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

This study aims to address the unmet medical need of participants with metastatic colorectal cancer (mCRC) who have previously been treated with irinotecan, oxaliplatin, a fluoropyrimidine, and bevacizumab, by demonstrating an overall surv…

Sponsor: EMD Serono Research & Development Institute, Inc.
NCT ID: NCT07549412
Sites in Texas:
  • Texas Oncology, P.A. - Abilene - 300210366 — Abilene, Texas
  • Texas Oncology-South Austin — Austin, Texas
  • Texas Oncology DFW — Bedford, Texas
  • Texas Oncology- San Antonio — San Antonio, Texas
  • Texas Oncology, P.A. - Tyler — Tyler, Texas
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Academic/Other

Randomizing Two Radiotherapy Boost Options to Avoid Rectal Cancer Surgery

A randomized study of 131 patients. Patients with a clinical T2-3 N0-1 rectal cancer will be randomized to two arms (arm A: standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 …

Sponsor: Sir Mortimer B. Davis - Jewish General Hospital
NCT ID: NCT03051464
Sites in Texas:
  • UT Southwestern Medical Center — Dallas, Texas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…

Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in Texas:
  • UT Southwestern Medical Center — Dallas, Texas
  • Local Institution - 2127 — Houston, Texas
  • MD Anderson Cancer Center — Houston, Texas
  • Local Institution - 2146 — Kingwood, Texas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…

Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in Texas:
  • Texas Oncology - Central/South Texas — Austin, Texas
  • Mary Crowley Cancer Research — Dallas, Texas
  • Texas Oncology - Baylor Charles A. Sammons Cancer Center — Dallas, Texas
  • Texas Oncology - Northeast Texas — Flower Mound, Texas
  • Oncology Consultants — Houston, Texas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current sub…

Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06445062
Sites in Texas:
  • Baylor College of Medicine — Houston, Texas
  • The University of Texas MD Anderson Cancer Center — Houston, Texas
  • NEXT Oncology Dallas — Irving, Texas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

FOG-001 in Locally Advanced or Metastatic Solid Tumors

The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).

Sponsor: Parabilis Medicines, Inc.
NCT ID: NCT05919264
Sites in Texas:
  • The University of Texas MD Anderson Cancer Center — Houston, Texas
  • South Texas Accelerated Research Therapeutics, LLC — San Antonio, Texas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been com…

Sponsor: Merus B.V.
NCT ID: NCT03526835
Sites in Texas:
  • Texas Oncology — Dallas, Texas
  • Oncology Consultants — Houston, Texas
  • Texas Oncology — Tyler, Texas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment wa…

Sponsor: Boehringer Ingelheim
NCT ID: NCT06324357
Sites in Texas:
  • The Methodist Hospital Research Institute — Houston, Texas
  • The University of Texas MD Anderson Cancer Center — Houston, Texas
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain

A randomized study to determine safety and efficacy of a series of subcutaneous (SC) injections of HAL in patients with CINP, compared to matching placebo injections. After that, subjects may have the option to enter an Open Label extensio…

Sponsor: Dogwood Therapeutics Inc.
NCT ID: NCT06848348
Sites in Texas:
  • Central Recruiting Site — Houston, Texas
  • Central Recruiting Site — McAllen, Texas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.

Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06128551
Sites in Texas:
  • Mary Crowley Cancer Research — Dallas, Texas
  • MD Anderson — Houston, Texas
  • NEXT Dallas — Irving, Texas
  • NEXT Oncology San Antonio — San Antonio, Texas
  • START Texas — San Antonio, Texas
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess change in disease activity when telisotuzumab adizutecan is given alone compared to standard of care (SOC) given al…

Sponsor: AbbVie
NCT ID: NCT07023289
Sites in Texas:
  • Texas Oncology - Central/South Texas /ID# 275154 — Austin, Texas
  • The Center For Cancer And Blood Disorders /ID# 278512 — Fort Worth, Texas
  • Texas Oncology-Grapevine /ID# 275155 — Grapevine, Texas
  • The University of Texas MD Anderson Cancer Center /ID# 273539 — Houston, Texas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Network

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…

Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Texas:
  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center — Houston, Texas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.

Sponsor: Revolution Medicines, Inc.
NCT ID: NCT05379985
Sites in Texas:
  • University of Texas at Austin — Austin, Texas
  • Mary Crowley Cancer Research — Dallas, Texas
  • The University of Texas MD Anderson Cancer Center — Houston, Texas
  • Next Oncology — San Antonio, Texas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…

Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in Texas:
  • Texas Oncology - West Texas — Amarillo, Texas
  • Texas Oncology, P.A. — Dallas, Texas
  • Texas Oncology Gulf Coast — Pearland, Texas
View on ClinicalTrials.gov →

Showing 25 of 116 trials with sites in Texas. See all colorectal cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-08-10